Revenue and net profit declined year-over-year due to industry headwinds, but the company expanded its plasma resources, advanced innovative biologics, and maintained strong market leadership. Major investments in R&D and digital transformation support future growth, while risks include plasma costs and FX volatility.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.